These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 26087869)

  • 1. Does ligand-receptor mediated competitive effect or penetrating effect of iRGD peptide when co-administration with iRGD-modified SSL?
    Zhang WQ; Yu KF; Zhong T; Luo LM; Du R; Ren W; Huang D; Song P; Li D; Zhao Y; Wang C; Zhang X
    J Drug Target; 2015 Dec; 23(10):897-909. PubMed ID: 26087869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation.
    Yu KF; Zhang WQ; Luo LM; Song P; Li D; Du R; Ren W; Huang D; Lu WL; Zhang X; Zhang Q
    Int J Nanomedicine; 2013; 8():2473-85. PubMed ID: 23885174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid-paclitaxel (CLA-PTX) on B16-F10 melanoma.
    Du R; Zhong T; Zhang WQ; Song P; Song WD; Zhao Y; Wang C; Tang YQ; Zhang X; Zhang Q
    Int J Nanomedicine; 2014; 9():3091-105. PubMed ID: 25028548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates.
    Wang K; Zhang X; Liu Y; Liu C; Jiang B; Jiang Y
    Biomaterials; 2014 Oct; 35(30):8735-47. PubMed ID: 25023394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cellular toxicity and anti-tumor efficacy of iRGD modified doxorubixin loaded sterically stabilized liposomes].
    Zhao B; Fan YC; Wang XQ; Dai WB; Zhang Q; Wang XL
    Yao Xue Xue Bao; 2013 Mar; 48(3):417-22. PubMed ID: 23724658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comprehensive study of iRGD-modified liposomes with improved chemotherapeutic efficacy on B16 melanoma.
    Dai W; Fan Y; Zhang H; Wang X; Zhang Q; Wang X
    Drug Deliv; 2015 Jan; 22(1):10-20. PubMed ID: 24735248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased antitumor activity of tumor-specific peptide modified thymopentin.
    Lao X; Li B; Liu M; Chen J; Gao X; Zheng H
    Biochimie; 2014 Dec; 107 Pt B():277-85. PubMed ID: 25236717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue-penetrating delivery of compounds and nanoparticles into tumors.
    Sugahara KN; Teesalu T; Karmali PP; Kotamraju VR; Agemy L; Girard OM; Hanahan D; Mattrey RF; Ruoslahti E
    Cancer Cell; 2009 Dec; 16(6):510-20. PubMed ID: 19962669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. iRGD-mediated core-shell nanoparticles loading carmustine and O
    Liu C; Yao S; Li X; Wang F; Jiang Y
    J Drug Target; 2017 Mar; 25(3):235-246. PubMed ID: 27646474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes.
    Simón-Gracia L; Hunt H; Scodeller P; Gaitzsch J; Kotamraju VR; Sugahara KN; Tammik O; Ruoslahti E; Battaglia G; Teesalu T
    Biomaterials; 2016 Oct; 104():247-57. PubMed ID: 27472162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma.
    Schmithals C; Köberle V; Korkusuz H; Pleli T; Kakoschky B; Augusto EA; Ibrahim AA; Arencibia JM; Vafaizadeh V; Groner B; Korf HW; Kronenberger B; Zeuzem S; Vogl TJ; Waidmann O; Piiper A
    Cancer Res; 2015 Aug; 75(15):3147-54. PubMed ID: 26239478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A tumor-penetrating peptide modification enhances the antitumor activity of thymosin alpha 1.
    Lao X; Liu M; Chen J; Zheng H
    PLoS One; 2013; 8(8):e72242. PubMed ID: 23977262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. iRGD: A Promising Peptide for Cancer Imaging and a Potential Therapeutic Agent for Various Cancers.
    Zuo H
    J Oncol; 2019; 2019():9367845. PubMed ID: 31346334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zerumbone Induces Apoptosis in Breast Cancer Cells by Targeting αvβ3 Integrin upon Co-Administration with TP5-iRGD Peptide.
    E M Eid E; S Alanazi A; Koosha S; A Alrasheedy A; Azam F; M Taban I; Khalilullah H; Sadiq Al-Qubaisi M; A Alshawsh M
    Molecules; 2019 Jul; 24(14):. PubMed ID: 31337024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis.
    Sugahara KN; Scodeller P; Braun GB; de Mendoza TH; Yamazaki CM; Kluger MD; Kitayama J; Alvarez E; Howell SB; Teesalu T; Ruoslahti E; Lowy AM
    J Control Release; 2015 Aug; 212():59-69. PubMed ID: 26071630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy.
    Sha H; Zou Z; Xin K; Bian X; Cai X; Lu W; Chen J; Chen G; Huang L; Blair AM; Cao P; Liu B
    J Control Release; 2015 Feb; 200():188-200. PubMed ID: 25553823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activatable iRGD-based peptide monolith: Targeting, internalization, and fluorescence activation for precise tumor imaging.
    Cho HJ; Lee SJ; Park SJ; Paik CH; Lee SM; Kim S; Lee YS
    J Control Release; 2016 Sep; 237():177-184. PubMed ID: 27349354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-administration of kla-TAT peptide and iRGD to enhance the permeability on A549 3D multiple sphere cells and accumulation on xenograft mice.
    Hu C; Chen X; Huang Y; Chen Y
    Chem Biol Drug Des; 2018 Aug; 92(2):1567-1575. PubMed ID: 29722179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer therapy with iRGD as a tumor-penetrating peptide.
    Thirumalai A; Girigoswami K; Pallavi P; Harini K; Gowtham P; Girigoswami A
    Bull Cancer; 2023 Dec; 110(12):1288-1300. PubMed ID: 37813754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. iRGD-modified lipid-polymer hybrid nanoparticles loaded with isoliquiritigenin to enhance anti-breast cancer effect and tumor-targeting ability.
    Gao F; Zhang J; Fu C; Xie X; Peng F; You J; Tang H; Wang Z; Li P; Chen J
    Int J Nanomedicine; 2017; 12():4147-4162. PubMed ID: 28615942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.